Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
According to the company, the design of the camera was developed to meet the needs of general healthcare providers, including primary care, optometry, retail health clinics and home health settings, and ensure accessibility and practicality in these environments.
Read more…
The NHS is to be allowed to hire physician associates (PA) from Ghana, Zimbabwe and Bangladesh, despite concerns over the quality of their training.
Doctors have been in revolt over the plan to increase the number of PAs and AAs…
Attendees
Sponsors and Exhibitors
AI Training for Doctors Workshops
Contact us